Literature DB >> 11477077

Role of cysteine residues in structural stability and function of a transmembrane helix bundle.

C B Karim1, M G Paterlini, L G Reddy, G W Hunter, G Barany, D D Thomas.   

Abstract

To study the structural and functional roles of the cysteine residues at positions 36, 41, and 46 in the transmembrane domain of phospholamban (PLB), we have used Fmoc (N-(9-fluorenyl)methoxycarbonyl) solid-phase peptide synthesis to prepare alpha-amino-n-butyric acid (Abu)-PLB, the analogue in which all three cysteine residues are replaced by Abu. Whereas previous studies have shown that replacement of the three Cys residues by Ala (producing Ala-PLB) greatly destabilizes the pentameric structure, we hypothesized that replacement of Cys with Abu, which is isosteric to Cys, might preserve the pentameric stability. Therefore, we compared the oligomeric structure (from SDS-polyacrylamide gel electrophoresis) and function (inhibition of the Ca-ATPase in reconstituted membranes) of Abu-PLB with those of synthetic wild-type PLB and Ala-PLB. Molecular modeling provides structural and energetic insight into the different oligomeric stabilities of these molecules. We conclude that 1) the Cys residues of PLB are not necessary for pentamer formation or inhibitory function; 2) the steric properties of cysteine residues in the PLB transmembrane domain contribute substantially to pentameric stability, whereas the polar or chemical properties of the sulfhydryl group play only a minor role; 3) the functional potency of these PLB variants does not correlate with oligomeric stability; and 4) acetylation of the N-terminal methionine has neither a functional nor a structural effect in full-length PLB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11477077     DOI: 10.1074/jbc.M104006200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure.

Authors:  Elizabeth L Lockamy; Razvan L Cornea; Christine B Karim; David D Thomas
Journal:  Biochem Biophys Res Commun       Date:  2011-04-12       Impact factor: 3.575

2.  Structure of the Na,K-ATPase regulatory protein FXYD1 in micelles.

Authors:  Peter Teriete; Carla M Franzin; Jungyuen Choi; Francesca M Marassi
Journal:  Biochemistry       Date:  2007-05-19       Impact factor: 3.162

3.  Packing of apolar side chains enables accurate design of highly stable membrane proteins.

Authors:  Marco Mravic; Jessica L Thomaston; Maxwell Tucker; Paige E Solomon; Lijun Liu; William F DeGrado
Journal:  Science       Date:  2019-03-29       Impact factor: 47.728

4.  Accurate quantitation of phospholamban phosphorylation by immunoblot.

Authors:  Naa-Adjeley Ablorh; Tyler Miller; Florentin Nitu; Simon J Gruber; Christine Karim; David D Thomas
Journal:  Anal Biochem       Date:  2012-02-03       Impact factor: 3.365

5.  Protein-protein interactions in calcium transport regulation probed by saturation transfer electron paramagnetic resonance.

Authors:  Zachary M James; Jesse E McCaffrey; Kurt D Torgersen; Christine B Karim; David D Thomas
Journal:  Biophys J       Date:  2012-09-19       Impact factor: 4.033

6.  Calcium-Dependent Structural Dynamics of a Spin-Labeled RyR Peptide Bound to Calmodulin.

Authors:  Cheng Her; Jesse E McCaffrey; David D Thomas; Christine B Karim
Journal:  Biophys J       Date:  2016-12-06       Impact factor: 4.033

7.  Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer.

Authors:  Elena V Rosca; Jacob E Koskimaki; Niranjan B Pandey; Antonio C Wolff; Aleksander S Popel
Journal:  Cancer Biol Ther       Date:  2011-11-01       Impact factor: 4.742

8.  Phospholamban structural dynamics in lipid bilayers probed by a spin label rigidly coupled to the peptide backbone.

Authors:  Christine B Karim; Tara L Kirby; Zhiwen Zhang; Yuri Nesmelov; David D Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

9.  Development of a Sensitive Assay for SERCA Activity Using FRET Detection of ADP.

Authors:  Meng Jing; Raffaello Verardi; Gianluigi Veglia; Michael T Bowser
Journal:  Anal Methods       Date:  2014-03-07       Impact factor: 2.896

10.  Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A.

Authors:  Amy D Hanna; Alex Lam; Steffi Tham; Angela F Dulhunty; Nicole A Beard
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.